pembrolizumab,rivoceranib,lenvatinib,camrelizumab,tislelizumab
merck,elevar therapeutics,eisai,jiangsu hengrui pharmaceuticals,beigene,novartis
['hcc', 'impact,(-impacte),(-impacti),(-impactf)', 'camrelizumab', 'rivoceranib', 'pembro', 'lenva']
#esmo22 negative &amp; positive results from phase 3 trials in #hcc that could impact the clinical practice will be discussed in few min! pembro+lenva camrelizumab+rivoceranib tislelisumab 
Independent and international group of experts in Liver oncology. Part of https://t.co/GxDpwbRI4D

#HCC #MedEd #oncology #LiverTwitter